News & Events
2015 Taubman Institute Symposium - CME Information
About the 8th Annual Taubman Institute Symposium
CME Information for Attendees
Target audience: Open to the general public, physicians, researchers and other members of the science community
Purpose and expected results: Our educational objective is to improve understanding of the use of deep-brain stimulation techniques to restore function in patients with Parkinson’s disease and other movement disorders. After this educational symposium, participants will be able to apply advanced knowledge of medical discovery and therapies to patient treatment.
10:00 a.m. Welcome and introduction, Dr. Eva Feldman, Taubman institute Director
10:10 a.m. Dr. Parag Patil, Taubman Emerging Scholar, UMHS Professor of Neurosurgery
“Using neural engineering and brain pacemakers to treat disorders of movement. “
10:30 a.m. Dr Henry Paulson, Taubman Scholar, UMHS Professor of Neurology
“Toward treatment for polyglutamine diseases”
10:50 a.m. Presentation of the 2015 Taubman Prize, Dr. Feldman and Taubman Family
11:00 a.m. Keynote Address, Dr. Mahlon DeLong, Taubman Prize recipient and Professor of Neurology at Emory University
“Basal Ganglia Circuit Disorders: Role and Rational for Neuromodulation”
11:45 a.m. Question and Answer Period
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians. The University of Michigan Medical School designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
An Evening of Art + Science 2016
Dr. Eva Feldman to be honored at the Michigan Israel Business Bridge Ambassador Awards Dinner Oct. 14
Ann Arbor — Taubman Institute Director Eva L. Feldman, M.D., Ph.D. is the 2015 recipient of the Chuck Newman Impact Award from the Michigan Israel Business Bridge, the organization has announced.
Dr. Feldman will accept the award at the MIBB’s Ambassador Awards dinner on Oct. 14 at The Reserve in Birmingham.
The award, named for the MIBB’s co-founder, is annually presented to individuals who personify MIBB’s goal of linking Michigan and Israel.
Dr. Feldman is a leading researcher in the quest for a cure for ALS and is a professor on the faculty of the University of Michigan Medical School as well as a practicing physician.
Both as director of the A. Alfred Taubman Medical Research Institute and in her own laboratory work as a clinician-scientist, has been instrumental in several collaborations among scientists in both countries. In addition, Dr. Feldman serves as an advisor to the United States-Israel Binational Science Foundation, which funds such scientific partnerships.
Among other endeavors, Dr. Feldman has been working with Dr. Benjamin Reubinoff, Director of the Human Embryonic Stem Cell Research Center at Hadassah Medical Center in Jerusalem on Stem Cell Research since 2009. The team has received a grant from the United States-Israel Binational Science Foundation to develop in vitro human tissue containing the genetic defects for ALS, which will enable scientists to test new therapies in the laboratory.
Dr. Feldman also has taken a leadership role in exchanging discovery and ideas with Israel-based researchers by inviting several leading scientists from Hadassah University in Jerusalem to visit the University of Michigan as visiting professors.
Ticket and sponsorship information for the Ambassador Awards event is available at www.michiganisrael.com
The Michigan Israel Business Bridge is a non-profit dedicated to promoting business partnerships between Michigan and Israel. The organization facilitates business and investment opportunities between Michigan and Israel for their mutual economic benefit.MIBB was co-founded in 2007 by Chuck Newman and Susan Herman, with the support of business people of Michigan.
Taubman Institute offers law lectures for physicians, med students
Perplexed by legal topics ranging from HIPAA to employment contracts?
Free lectures on the latest topics and trends are being offered this fall to UMHS physicians and medical students complements of the A. Alfred Taubman Medical Research Institute.
Both one-hour talks will take place at the Danto Auditorium at the U-M Cardiovascular Center. Attendees will receive an update on the latest in regulatory issues, from patient privacy to physician referrals, as well as tips for avoiding common misperceptions and pitfalls. A question-and-answer session is included in both seminars.
October 7, 4 p.m.: Health Law Overview for Residents and Medical Students
Geared specifically to students and early-career physicians, topics include:
- Physician contracting, including what to look out for when signing your first contract
- Overview of important healthcare laws affecting physicians, including the Stark law, the anti-kickback statute, the anti-markup rule, and HIPAA
- Legal basics, including the difference between professional and non-professional entities, and the difference between limited liability companies and corporations.
- Resident performance and discipline
- Trends in health law
- Q & A session
November 4, 4 p.m.: Legal Issues Affecting Physicians and Health care Entities.
This talk, suitable for physicians and practice managers, will cover:
- Physician referrals and business transactions under the Stark law and anti-kickback statute, including common pitfalls
- Basics of physician contracting
- HIPAA and protected health information
- Legal issues in caring for the elderly
- Overview of Michigan's public health code
- Overview of M & A activity and trends, and clinical integration under the ACA
- Corporate Practice of Medicine Doctrine, and when a healthcare company must register as a "professional entity"
- Q&A session
No registration is required. Click here for a map to the Cardiovascular Center.
2016 Art+Science event set for April 21
Fundraising auction moves to Ann Arbor
For the third consecutive year, the scholars of the Taubman Institute will team up with leading contemporary artists for an exploration of the creative process in their respective fields.
The resulting artwork will be auctioned on April 21, 2016 to benefit life-saving translational medical research at the University of Michigan.
Our 2016 event will take place at the stunning A. Alfred Taubman Biomedical Science Research Building on the U-M campus, and will feature cocktails, dinner, tours of Taubman Scholar laboratories and much more!
Details of ticket sales, sponsorships and more will unfold in coming months. Check back for updates or click here to sign up for Taubman Institute e-mail alerts.
Call for abstracts and art!
Taubman Institute Eighth Annual Symposium
Friday, October 16, 2015
Posters: 8:30 a.m. – 10 a.m. – AAT-BSRB lobby
Speakers: 10 a.m. – noon – Kahn Auditorium inside AAT-BSRB
Keynote Speaker: 2015 Taubman Prize recipient Mahlon DeLong, M.D.
Professor of Neurology, Emory University School of Medicine
In conjunction with its annual symposium, the Taubman Institute is sponsoring two competitions for U-M scientists: A poster presentation and an art contest.
The posters will be displayed from 8:30 a.m. on Oct. 16 in the lobby of the A. Alfred Taubman Biomedical Science Research Building. Winning images in the art contest will be displayed and featured in the symposium program.
Cash prizes for the top three submissions in each category will be awarded at the close of the symposium. Contestants must be present to claim prizes.
CALL FOR ABSTRACTS
Submit abstracts for poster presentations on original basic science, translational, health services, or clinical research and vie for cash prizes!
1st prize: $300
2nd prize: $200
Winners must be present at symposium to receive prizes.
Abstract submission requirements:
- Include title, authors (with degrees and affiliations), and contact information for the presenting author.
- Abstracts should be structured and include: Introduction and Objective, Methods, Results, and Conclusion.
- Abstract length is limited to 300 words.
- Judging criteria will include originality of concept, sophistication of methodology, and clarity of presentation.
- Applicants will be notified of abstract acceptance by October 1, 2015.
Abstract Submission Deadline: SEPTEMBER 25, 2015
Submit art based on your biomedical research to be considered for the cover art for the symposium brochure and vie for cash prizes!
1st prize: $300
2nd prize: $200
3rd prize: $100
Prize winners will be announced at the poster session preceding the symposium
Image submission requirements:
- Art may be any two-dimensional medium such as photograph, screenshot, original drawing, painting, collage, etc.
- Art must be based on some facet of your own or your laboratory’s research at the University of Michigan.
- Provide a JPEG or TIF version of the work with an explanatory paragraph of 100 words or less (tell us what the art depicts and who created it)
- Students, post-doctoral fellows, faculty, and staff are eligible to submit.
- By submitting your original work of art, you give permission for submissions to be displayed by the Taubman Institute at its annual symposium as well as on the institute's website and in other related materials.[S4]
Cover Art Submission Deadline: SEPTEMBER 25, 2015
Taubman Prize awarded to Mahlon DeLong, M.D., of Emory University
Clinician-scientist developed Parkinson’s disease breakthrough
Ann Arbor, Mich. — A physician-scientist whose work has improved quality of life for tens of thousands of Parkinson’s disease patients is the recipient of the 2015 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced.
Mahlon DeLong, M.D., Professor of Neurology at the Emory University School of Medicine, will receive the $100,000 prize in recognition of his contributions to the treatment of Parkinson’s disease.
DeLong’s research – spanning a 40-year career in medicine and science – identified the anatomical brain circuits involved in the clinical features of Parkinson’s disease and a novel target for surgical intervention, the subthalamic nucleus, a portion of the basal ganglia, brain structures located deep in the brain.
This finding paved the way for the application of high frequency deep-brain stimulation (DBS) of the subthalamic nucleus, a technique now used worldwide for advanced Parkinson’s disease patients. More than 100,000 individuals have received the treatment, which suppresses tremor and other motor impairments, and improves the ability to carry out the normal activities of daily living.
“Dr. DeLong’s contribution to improved care and quality of life for patients with devastating movement disorders is remarkable,” said Eva Feldman, M.D., Ph.D., director of the Taubman Institute, and the Russell N. DeJong Professor of Neurology at the U-M Medical School. “He exemplifies the ethos of the dedicated clinician-scientist. We are honored to recognize his extraordinary contributions by awarding him the Taubman Prize.”
DeLong was selected by a national panel of eminent medical science experts from among dozens of nominees for the Taubman Prize. Over decades he and his colleagues have mapped brain activity and deciphered the complex pathways and circuitry involved with the processing of motor functions, thoughts and emotions. Insights gained through his basic research, animal models and experiments eventually led to a clearer understanding of the abnormalities in brain circuits in animal models of Parkinson’s and how interruption of a key portion of the motor circuits could dramatically improve clinical features.
DeLong’s studies contributed greatly to the revival of surgical approaches for treating movement disorders. The development of the novel technique of high frequency deep-brain stimulation, using implanted electrodes, by Dr. Alim Louis Benabid in Grenoble, France, when applied to the subthalamic nucleus in patients with Parkinson’s produced a similar result as surgical interruption. DBS, because of its less invasive, reversible and adjustable features, rapidly replaced direct, irreversible destructive lesioning approaches.
DeLong, the William Timmie Professor of Neurology at Emory University School of Medicine, will present the keynote address at the Taubman Institute’s annual symposium on Oct. 16, 2015 at the Kahn Auditorium on the U-M medical campus. The symposium is open to the general public.
The Taubman Prize was established in 2012 to recognize outstanding translational medical research beyond the University of Michigan. It includes a $100,000 award and is presented each year to the non-U-M clinician-scientist who has done the most to transform laboratory discoveries into clinical applications for patients suffering from disease.
Previous recipients are:
2014: Carl June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, for discoveries related to immunotherapy for leukemia using patients’ own T cells.
2013: Brian Druker, M.D., of the Oregon Health & Science University and Charles Sawyers, M.D., of Memorial Sloan Kettering Cancer Center, for their discoveries related to chronic myeloid leukemia.
2012: Hal Dietz, M.D., of Johns Hopkins University for his discoveries related to connective tissue disease.
About Mahlon DeLong, M.D.: DeLong is a key faculty leader of The Jean and Paul Amos Parkinson's Disease and Movement Disorders Research Program. He also is co-director and founder of ENTICe (Emory Neuromodulation and Technology Innovation Center), whose goal is to foster advancement of neuromodulation and the development of innovative neuromodulation technologies for the treatment of neurological and psychiatric disorders.
He is a member of the Institute of Medicine, a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science (AAAS), an elected member of the Johns Hopkins Society of Scholars. He is scientific director of the Dystonia Medical Research Foundation and a member of the Scientific Advisory Board of the American Parkinson Disease Association.
DeLong received his undergraduate degree from Stanford University and his medical degree from Harvard University. He worked as a researcher at the National Institute of Mental Health at the National Institutes of Health (1968-1973) completed his residency in Neurology at Johns Hopkins School of Medicine and was a member of the Johns Hopkins faculty (1975-1989). In 1989 he joined Emory University School of Medicine, where he served as chair of the Department of Neurology (1989-2003).
DeLong has received numerous awards including the 2013 Breakthrough Prize in Life Sciences and the 2014 Lasker Award, which recognizes excellence in research aimed at curing intractable diseases and extending human life. He also received the 2009 American Academy of Neurology Movement Disorders Research Award and the 2008 Movement Disorders Society Lifetime Achievement Award.
He is a member of the Institute of Medicine, a fellow of the American Academy of Arts & Sciences, a fellow of the American Association for the Advancement of Science (AAAS), an elected member of the Johns Hopkins Society of Scholars, and is a past chair of the Society for Neuroscience. He is scientific director of the Dystonia Medical Research Foundation and a member of the Scientific Advisory Board of the American Parkinson Disease Association.
About the A. Alfred Taubman Medical Research Institute: In 2007 Michigan businessman, philanthropist and noted patron of the arts A. Alfred Taubman provided the initial funds to establish the institute bearing his name at the University of Michigan Medical School. Its mission is to provide the university’s finest medical scientists the freedom, resources and collaborative environment they need to push the boundaries of medical discovery, to produce breakthroughs in cures to speed the development of effective treatment for some of the most devastating illnesses. Currently, nearly 40 Taubman Scholars are advancing their research with the assistance of grants from the institute.
Dr. Max Wicha appointed to National Cancer Advisory Board
President Barak Obama announced his selection of Max S. Wicha, M.D., as one of five new appointees to the National Cancer Advisory Board.
Wicha, the Madeline and Sidney Forbes Professor of Oncology at the University of Michigan Comprehensive Cancer Center, will serve on the 18-member board for six years.
“I am honored that these talented individuals have decided to serve our country. They bring their years of experience and expertise to this Administration, and I look forward to working with them,” Obama said in a statement.
The NCAB and the President’s Cancer Panel are the only advisory bodies at either the National Institutes of Health or the Department of Health and Human Services whose members are appointed by the president. The primary task of the NCAB is to advise the secretary of Health and Human Services, the director of the National Cancer Institute, and ultimately the president of the United States on a range of issues affecting the nation’s cancer program and, specifically, NCI operations. The NCAB reviews and recommends grants and cooperative agreements following technical and scientific peer review.
Wicha founded the U-M Comprehensive Cancer Center and served as director for 27 years. He is a renowned cancer researcher who was part of the team that first identified cancer stem cells in a solid tumor, finding them in breast cancer. His lab continues to look at cancer stem cells to help improve treatments for metastatic breast cancer.
Wicha also serves as the deputy director of the A. Alfred Taubman Medical Research Institute.
Art auction helps expand Emerging Scholars Program
Two festive events have led to an expansion of the Taubman Institute's Emerging Scholars Program, said Eva L. Feldman, M.D., Ph.D., director of the institute.
Held in May, "Cures Are an Art Form" and "An Evening of Art + Science" each celebrated collaborations among Taubman Scholars -- U-M's eminent clinician-scientists -- and leading contemporary artists. The artists and scientists met for ab and studio tours, and discussions about the nature of ideas and curiosity and discovery in their respective fields. Then, the artists produced works of creativity inspired by the research of scholars working in fields as diverse as ophthalmology, dermatology, oncology and brain diseases.
The artwork was showcased at "Cures Are an Art Form" at Detroit's new nightclub Populux, and an online auction culminated May 14 during the gala "An Evening of Art + Science" at the Detroit Institute of Arts.
Through the sale of tickets, sponsorships and most importantly the original works of art, the Taubman Institute realized sufficient funds to expand the Emerging Scholars Program, which helps to support the up-and-coming generation of biomedical researchers.
"We are delighted that our second annual Evening of Art + Science was such a success," said Feldman. "Our deepest thanks to all who contributed and attended. I think we all enjoyed the opportunity to contemplate both art and science in new ways, and to enlarge our understanding of the intersection of both worlds. The monies we have raised will go directly to the support of early-career clinician-researchers, keeping the pipeline of new medical breakthroughs full for future generations."
Click here to view the photo gallery.
Science-inspired artwork up for sale!
The Taubman Institute Evening of Art + Science, held May 14 at the Detroit Institute of Arts, was a gala success.
Select artwork, below, still is available for purchase, with proceeds to benefit the Taubman Institute's Emerging Scholars Program. For more information, contact Glen Walker at (734) 615-7282 or
About the Art + Science Collaboration
Twenty physician-researchers of the A. Alfred Taubman Medical Research Institute – global thought leaders in areas like cancer, cardiovascular health, ALS and more – teamed up this year with painters, sculptors, jewelers and other creative virtuosos for mind-bending conversations about the intersection of discovery and creativity in their respective fields.
In visits to one another’s labs and studios, the artists and scientists found common ground in the process each uses to leap challenges, to refine new techniques and to test novel hunches and ideas.
In the laboratory, the process leads to life-giving new treatments and cures. In the studio, the journey of inspiration results in works of beauty and expression. The resulting one-of-a-kind creations — in media ranging from oils to textiles to gemstones — are sold to fund the Taubman Institute's Emerging Scholars grants.
Aimed at launching the laboratories of U-M's best and brightest young doctors, these grants of $50,000 per year for three years help ensure the next generation of medical breakthroughs. In just a few short years, Taubman Emerging Scholars have initiated nine human clinical trials of new treatments in fields ranging from cancer to inflammatory diseases. With 16 Emerging Scholars now being supported – and two dozen more worthy candidates vetted and ready for funding – it’s a program that aims for, and achieves, fast results for patients who can’t wait.
Dr. Eva Feldman: Alfred Taubman as mentor, leader, friend
The source of his greatness lay in his willingness to challenge conventional thinking.
2016 Art+Science Event Set for April 21
Save the date for another gala art auction to benefit the life-saving research of the Taubman Scholars.
Taubman Scholars: Reflections on Alfred Taubman
Eminent scientists say his curiosity, interest and vision changed the course of medical science.
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.